In the days following Tuesday’s vote, the FDA is expected to issue an emergency use authorization to allow the vaccine to be administered to younger people, Stat News reported.
An FDA analysis confirmed results from Pfizer and BioNTech, which found that the vaccine is nearly 91% effective at preventing symptomatic infection in children between the ages of 5 and 11.
Dr.
Matthew Oster, of the CDC’s COVID-19 Vaccine Task Force, said officials have received 1,640 reports of myocarditis in vaccinated people under 30.
“Myocarditis is a rare but important adverse event following COVID-19 vaccination, and not all myocarditis is the same,” Oster said, noting that people who experienced myocarditis after vaccination tended to recover quickly.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.